Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

Analysis of Liquidity Ratios
Quarterly Data

Microsoft Excel

Liquidity Ratios (Summary)

Vertex Pharmaceuticals Inc., liquidity ratios (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Current ratio 2.69 2.47 2.52 3.50 3.99 4.08 4.14 4.28 4.83 4.70 4.50 4.75 4.46 4.62 4.61 4.39 4.33 3.72 3.72 3.54
Quick ratio 2.17 2.08 2.10 3.15 3.60 3.74 3.82 3.95 4.46 4.28 4.14 4.37 4.04 4.21 4.16 4.06 4.02 3.46 3.47 3.27
Cash ratio 1.72 1.64 1.63 2.68 3.16 3.31 3.35 3.44 3.93 3.74 3.62 3.78 3.51 3.64 3.65 3.56 3.55 3.07 3.03 2.72

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Vertex Pharmaceuticals Inc. current ratio deteriorated from Q2 2024 to Q3 2024 but then improved from Q3 2024 to Q4 2024 exceeding Q2 2024 level.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Vertex Pharmaceuticals Inc. quick ratio deteriorated from Q2 2024 to Q3 2024 but then improved from Q3 2024 to Q4 2024 exceeding Q2 2024 level.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Vertex Pharmaceuticals Inc. cash ratio improved from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.

Current Ratio

Vertex Pharmaceuticals Inc., current ratio calculation (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in thousands)
Current assets 9,596,400 9,804,100 8,941,600 13,288,700 14,144,200 14,695,800 13,872,900 12,965,700 13,234,800 12,271,000 11,503,500 10,361,300 9,560,600 8,852,540 8,457,514 8,539,307 8,133,379 7,458,456 6,694,320 5,446,400
Current liabilities 3,564,600 3,973,100 3,547,200 3,795,900 3,547,400 3,599,400 3,352,100 3,026,200 2,742,100 2,609,300 2,556,200 2,180,200 2,142,000 1,914,264 1,836,448 1,944,050 1,877,533 2,004,026 1,798,640 1,538,750
Liquidity Ratio
Current ratio1 2.69 2.47 2.52 3.50 3.99 4.08 4.14 4.28 4.83 4.70 4.50 4.75 4.46 4.62 4.61 4.39 4.33 3.72 3.72 3.54
Benchmarks
Current Ratio, Competitors2
AbbVie Inc. 0.66 0.65 0.81 0.94 0.87 0.96 0.89 0.96 0.96 0.93 0.84 0.82 0.79 1.01 0.91 0.83 0.84 0.95 0.86 3.14
Amgen Inc. 1.26 1.32 1.26 1.42 1.65 2.86 2.77 3.14 1.41 1.68 1.53 1.44 1.59 1.64 1.31 1.66 1.81 2.28 2.18 1.59
Bristol-Myers Squibb Co. 1.25 1.24 1.16 1.11 1.43 1.18 1.39 1.42 1.25 1.42 1.44 1.32 1.52 1.47 1.54 1.56 1.58 1.67 1.47 1.66
Danaher Corp. 1.40 1.37 1.43 1.85 1.68 2.26 2.08 1.89 1.89 1.78 1.75 1.68 1.43 1.48 2.26 2.05 1.86 2.08 2.20 1.32
Eli Lilly & Co. 1.15 1.27 1.11 1.35 0.94 1.05 1.13 1.30 1.05 1.13 1.10 1.27 1.23 1.30 1.15 1.42 1.40 1.36 1.22 1.11
Gilead Sciences Inc. 1.60 1.26 1.14 1.08 1.43 1.34 1.02 1.28 1.29 1.30 1.43 1.48 1.27 1.37 1.36 1.37 1.40 3.25 2.33 3.04
Johnson & Johnson 1.11 1.03 1.07 1.17 1.16 1.21 1.12 1.07 0.99 1.43 1.42 1.39 1.35 1.34 1.39 1.28 1.21 1.48 1.25 1.31
Merck & Co. Inc. 1.36 1.36 1.47 1.25 1.25 1.38 1.28 1.44 1.47 1.46 1.39 1.40 1.27 1.31 1.31 1.02 1.02 1.30 1.32 1.11
Pfizer Inc. 1.17 1.00 0.86 1.05 0.91 2.38 2.12 1.37 1.22 1.59 1.42 1.39 1.40 1.39 1.37 1.48 1.35 1.40 1.42 1.03
Regeneron Pharmaceuticals Inc. 4.73 5.28 5.44 5.27 5.69 5.18 5.45 5.45 5.06 5.36 5.12 4.76 3.56 3.71 3.57 3.12 3.63 3.89 2.12 4.21
Thermo Fisher Scientific Inc. 1.66 1.63 1.72 1.70 1.75 1.63 1.42 1.27 1.48 1.74 1.65 1.56 1.50 3.19 2.78 2.53 2.13 2.93 2.62 2.32

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q4 2024 Calculation
Current ratio = Current assets ÷ Current liabilities
= 9,596,400 ÷ 3,564,600 = 2.69

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Vertex Pharmaceuticals Inc. current ratio deteriorated from Q2 2024 to Q3 2024 but then improved from Q3 2024 to Q4 2024 exceeding Q2 2024 level.

Quick Ratio

Vertex Pharmaceuticals Inc., quick ratio calculation (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in thousands)
Cash and cash equivalents 4,569,600 5,239,200 4,580,100 9,158,000 10,369,100 11,110,200 10,151,100 9,289,900 10,504,000 9,171,500 8,702,200 7,600,100 6,795,000 6,275,698 6,063,678 6,304,330 5,988,187 5,358,087 4,831,332 3,593,412
Marketable securities 1,546,300 1,285,300 1,215,400 1,013,300 849,200 818,000 1,085,200 1,124,200 274,500 599,200 551,200 638,000 729,900 685,187 644,315 619,638 670,710 792,971 619,437 596,984
Accounts receivable, net 1,609,400 1,750,600 1,656,100 1,793,200 1,563,400 1,538,700 1,556,200 1,547,800 1,442,200 1,385,200 1,332,900 1,292,800 1,136,800 1,100,372 929,142 977,551 885,352 791,917 791,768 845,269
Total quick assets 7,725,300 8,275,100 7,451,600 11,964,500 12,781,700 13,466,900 12,792,500 11,961,900 12,220,700 11,155,900 10,586,300 9,530,900 8,661,700 8,061,257 7,637,135 7,901,519 7,544,249 6,942,975 6,242,537 5,035,665
 
Current liabilities 3,564,600 3,973,100 3,547,200 3,795,900 3,547,400 3,599,400 3,352,100 3,026,200 2,742,100 2,609,300 2,556,200 2,180,200 2,142,000 1,914,264 1,836,448 1,944,050 1,877,533 2,004,026 1,798,640 1,538,750
Liquidity Ratio
Quick ratio1 2.17 2.08 2.10 3.15 3.60 3.74 3.82 3.95 4.46 4.28 4.14 4.37 4.04 4.21 4.16 4.06 4.02 3.46 3.47 3.27
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc. 0.43 0.44 0.59 0.72 0.63 0.71 0.63 0.66 0.69 0.69 0.61 0.56 0.56 0.75 0.65 0.61 0.60 0.68 0.58 2.88
Amgen Inc. 0.81 0.80 0.75 0.84 0.99 2.41 2.34 2.62 0.95 1.17 0.99 0.90 1.06 1.19 0.86 1.16 1.30 1.65 1.60 1.10
Bristol-Myers Squibb Co. 0.91 0.84 0.78 0.78 1.04 0.77 0.94 1.01 0.87 0.98 1.07 1.03 1.20 1.16 1.16 1.25 1.28 1.43 1.26 1.38
Danaher Corp. 0.83 0.84 0.85 1.34 1.18 1.76 1.52 1.34 1.30 1.19 1.13 1.08 0.89 0.93 1.67 1.51 1.36 1.52 1.59 0.92
Eli Lilly & Co. 0.59 0.63 0.61 0.68 0.52 0.58 0.63 0.79 0.63 0.71 0.67 0.77 0.80 0.79 0.67 0.83 0.85 0.79 0.68 0.64
Gilead Sciences Inc. 1.20 0.82 0.69 0.72 1.06 0.98 0.78 0.95 0.99 0.96 1.06 1.06 0.95 1.01 1.05 0.99 1.08 2.93 2.09 2.78
Johnson & Johnson 0.78 0.70 0.77 0.84 0.82 0.86 0.84 0.81 0.71 1.10 1.09 1.06 1.04 1.03 1.04 0.97 0.91 1.17 0.92 0.98
Merck & Co. Inc. 0.84 0.88 0.88 0.68 0.68 0.83 0.74 0.90 0.93 0.90 0.85 0.84 0.73 0.78 0.75 0.58 0.58 0.77 0.84 0.66
Pfizer Inc. 0.74 0.56 0.42 0.57 0.50 1.78 1.59 0.88 0.80 1.18 1.02 0.95 1.00 0.99 0.91 0.88 0.78 0.93 0.98 0.60
Regeneron Pharmaceuticals Inc. 3.86 4.34 4.43 4.40 4.82 4.31 4.53 4.54 4.16 4.37 4.20 3.95 2.98 3.03 2.92 2.39 2.86 3.02 1.61 3.38
Thermo Fisher Scientific Inc. 1.14 1.13 1.24 1.19 1.27 1.13 0.89 0.80 1.06 1.06 0.98 0.97 1.00 2.37 1.92 1.70 1.63 2.16 1.83 1.48

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q4 2024 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 7,725,300 ÷ 3,564,600 = 2.17

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Vertex Pharmaceuticals Inc. quick ratio deteriorated from Q2 2024 to Q3 2024 but then improved from Q3 2024 to Q4 2024 exceeding Q2 2024 level.

Cash Ratio

Vertex Pharmaceuticals Inc., cash ratio calculation (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in thousands)
Cash and cash equivalents 4,569,600 5,239,200 4,580,100 9,158,000 10,369,100 11,110,200 10,151,100 9,289,900 10,504,000 9,171,500 8,702,200 7,600,100 6,795,000 6,275,698 6,063,678 6,304,330 5,988,187 5,358,087 4,831,332 3,593,412
Marketable securities 1,546,300 1,285,300 1,215,400 1,013,300 849,200 818,000 1,085,200 1,124,200 274,500 599,200 551,200 638,000 729,900 685,187 644,315 619,638 670,710 792,971 619,437 596,984
Total cash assets 6,115,900 6,524,500 5,795,500 10,171,300 11,218,300 11,928,200 11,236,300 10,414,100 10,778,500 9,770,700 9,253,400 8,238,100 7,524,900 6,960,885 6,707,993 6,923,968 6,658,897 6,151,058 5,450,769 4,190,396
 
Current liabilities 3,564,600 3,973,100 3,547,200 3,795,900 3,547,400 3,599,400 3,352,100 3,026,200 2,742,100 2,609,300 2,556,200 2,180,200 2,142,000 1,914,264 1,836,448 1,944,050 1,877,533 2,004,026 1,798,640 1,538,750
Liquidity Ratio
Cash ratio1 1.72 1.64 1.63 2.68 3.16 3.31 3.35 3.44 3.93 3.74 3.62 3.78 3.51 3.64 3.65 3.56 3.55 3.07 3.03 2.72
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc. 0.14 0.17 0.31 0.44 0.34 0.38 0.27 0.24 0.31 0.36 0.29 0.23 0.28 0.43 0.30 0.31 0.30 0.33 0.25 2.50
Amgen Inc. 0.52 0.44 0.43 0.49 0.60 2.05 2.00 2.22 0.59 0.80 0.57 0.51 0.66 0.87 0.55 0.82 0.91 1.24 1.09 0.68
Bristol-Myers Squibb Co. 0.46 0.36 0.29 0.37 0.55 0.33 0.43 0.49 0.42 0.48 0.63 0.66 0.78 0.73 0.68 0.75 0.83 1.03 0.92 0.95
Danaher Corp. 0.31 0.36 0.35 0.90 0.71 1.31 1.02 0.85 0.71 0.64 0.53 0.49 0.32 0.35 1.07 0.93 0.82 0.94 0.99 0.52
Eli Lilly & Co. 0.12 0.14 0.12 0.14 0.11 0.11 0.15 0.23 0.13 0.18 0.18 0.19 0.26 0.28 0.22 0.26 0.29 0.30 0.20 0.14
Gilead Sciences Inc. 0.83 0.43 0.26 0.36 0.64 0.57 0.48 0.56 0.57 0.54 0.61 0.62 0.56 0.56 0.64 0.58 0.65 2.52 1.79 2.34
Johnson & Johnson 0.49 0.39 0.47 0.54 0.50 0.53 0.53 0.54 0.42 0.75 0.73 0.70 0.70 0.70 0.65 0.60 0.59 0.79 0.52 0.54
Merck & Co. Inc. 0.48 0.49 0.44 0.22 0.28 0.38 0.27 0.45 0.54 0.49 0.44 0.40 0.34 0.42 0.39 0.26 0.30 0.36 0.50 0.32
Pfizer Inc. 0.48 0.23 0.16 0.29 0.27 1.42 1.29 0.55 0.54 0.82 0.70 0.61 0.73 0.71 0.61 0.51 0.47 0.64 0.70 0.31
Regeneron Pharmaceuticals Inc. 2.28 2.68 2.80 2.94 3.17 2.75 2.88 2.89 2.46 2.44 2.49 2.34 1.45 1.56 1.05 1.09 1.33 1.29 0.85 1.95
Thermo Fisher Scientific Inc. 0.42 0.46 0.60 0.52 0.58 0.43 0.22 0.22 0.50 0.26 0.17 0.23 0.33 1.55 1.01 0.80 1.00 1.21 0.97 0.54

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q4 2024 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 6,115,900 ÷ 3,564,600 = 1.72

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Vertex Pharmaceuticals Inc. cash ratio improved from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.